Understanding the Full Implications of HIPAA for Pharmaceuticals
|Event Date/Time: Aug 05, 2002||End Date/Time: Aug 07, 2002|
The Institute for International Research is proud to bring you ‘HIPAA for Pharmaceuticals.’ This event is the most comprehensive conference currently offered that examines the full implications of HIPAA for pharmaceutical, biotech and medical device companies. Designed with the help of an expert advisory board and speaker faculty, it addresses all your HIPAA compliance needs over the course of three information-packed days.
On Day One we present four half-day workshops that are constructed to meet your level of HIPAA compliance informational needs:
B1. Preparing Your Pharmaceutical Company for HIPAA: A Practical Compliance Guide
This workshop is designed for pharmaceutical, biotech and medical device companies who have not yet started HIPAA compliance, or are in the very early stages.
B2. Conducting a HIPAA Compliance Risk Assessment
This workshop is designed for pharmaceutical, biotech and medical device companies who have started HIPAA compliance, but need to see assess how compliant they are and determine what further compliance measures need to be taken.
B3. Navigating the Legalities of HIPAA for Pharmaceuticals
This workshop is for the Legal Counsel and Regulatory Affairs professionals at pharmaceutical, biotech and medical device companies, enabling them to master all the legal intricacies of HIPAA.
B4. HIPAA and Sales & Marketing: the Implications for Pharmaceutical Marketing and Database-Building
This workshop is designed to meet the informational needs of sales and marketing professionals at pharmaceutical, biotech and medical device companies. Most of the information available on HIPAA refers to its impact on clinical research. There is little information detailing how sales and marketing, particularly CRM and eDetailing, is impacted. This workshop provides a step by step guide as to the implications of HIPAA and what contingency plans need to be put into place for sales and marketing initiatives.
On Day Two, the main conference opens. The main objective of this day is to provide you with the knowledge and tools needed to determine the level of HIPAA compliance you must meet and the strategies for meeting the HIPAA requirements with limited time and resources. More specifically we focus on: the job functions that are impacted by HIPAA; what their training needs are; developing a HIPAA compliance time schedule; assigning responsibility to ensure HIPAA specifications are met and determining the best allocation of limited resources for ensuring compliance. In addition, we examine how drugs and device companies’ partnerships and work practices with healthcare providers, CROs and clinical investigators are impacted by HIPAA; the implications of HIPAA on patient recruitment and IRBs; and understanding how HIPAA relates to 21 CFR Part 11.
Day Three takes a more in-depth look at how HIPAA impacts clinical research, sales and marketing processes and job functions. Specifically we examine patient authorizations; de-identification of data; the implications of HIPAA on conducting global research; data collection, authorization and use to market products within the HIPAA guidelines; how HIPAA impacts CRM and eDetailing; and the training needs of sales and marketing personnel. In addition we have a panel discussion on educating principal investigators and the physician community about best business practices with drugs and device companies under HIPAA.
With an expert speaker faculty comprising senior representatives from leading organizations such as: Astrazeneca, Aventis Pharmaceuticals, Pharmacia, Quintiles, and the Internet Healthcare Coalition, this conference meets all your current HIPAA learning objectives including:
Clearing the HIPAA confusion: the true implications for pharmaceutical, biotech and medical device companies
Understanding the full implications of HIPAA on clinical research processes and job responsibilities
Determining what needs to be done, when and by whom in pharmaceuticals to meet compliance deadlines
Examining how HIPAA will impact online and offline sales and marketing practices
Conducting a HIPAA compliance security risk assessment
Safeguarding relationships and partnerships with healthcare entities impacted by HIPAA
Understanding the internal training, resource allocation and business process re-engineering needs for HIPAA
HIPAA has such an extensive and hard-hitting impact across the entire business operations of drugs and device companies: clinical research; sales and marketing, particularly CRM and eDetailing; disease management; data collection and security; business processes and internal training. Therefore, take full advantage of this unique opportunity to meet with your industry colleagues to share and explore solutions to the same concerns and challenges you are all now facing with HIPAA.